Details of the Drug Formulaction

General Information of Drug Formulation (ID: F23947)

Formulation Name
Cabozantinib S-Malate eq 20mg base tablet
Company
Exelixis
Pharmaceutical Drug(s) in Formulation
Drug Name Drug ID Indication ICD 11 Status
Cabozantinib DMIYDT4 Medullary thyroid gland carcinoma Approved
Pharmaceutical Excipient(s) in Formulation
Excipient Name Excipient ID PubChem CID Functional Classification
Beta-D-lactose E00099 6134 Diluent; Dry powder inhaler carrier; Lyophilization aid
Carmellose sodium E00625 Not Available Disintegrant
Cellulose microcrystalline E00698 Not Available Adsorbent; Suspending agent; Diluent
Ferric hydroxide oxide yellow E00539 23320441 Colorant
Hydrophobic colloidal silica E00285 24261 Anticaking agent; Emulsion stabilizing agent; Glidant; Suspending agent; Viscosity-controlling agent
Hydroxypropyl cellulose E00632 Not Available Binding agent; Coating agent; Emulsifying agent; Film/Membrane-forming agent; Modified-release agent; Suspending agent; Viscosity-controlling agent
Hypromellose E00634 Not Available Coating agent
Magnesium stearate E00208 11177 lubricant
Titanium dioxide E00322 26042 Coating agent; Colorant; Opacifying agent
Triacetin E00080 5541 Humectant; Plasticizing agent; Solvent